ArticleHematological oncology2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort.
Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Newly diagnosed patients with non-Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidemiology of Outcomes (LEO) comorbidity index (LCI) as a sum of 10 comorbidities adapted from the Self-Report-Generated Charlson Comorbidity Index (SRG-CCI) for use in the LEO cohort, a national prospective study of newly diagnosed NHL. Of the 5502 participants with self-reported comorbidity data, 3107 (56.4%) were male and the mean age at diagnosis was 60.9 years (range, 18-99 years). The LCI ranged from 0 to 6, with 48.6% having 0, 30.2% having 1, 21.2% having 2 or more comorbidities. With a median follow-up of 62.4 months among surviving participants, 2099 patients had an event and 1219 died. Continuous LCI similarly predicted both 1-year mortality (c-statistic = 0.654) and OS (c-statistic = 0.655), while it showed a weaker but still statistically significant predictive ability for lymphoma-specific (c-statistics = 0.617) and event-free (c-statistic = 0.574) survival. Participants with 1 (HR = 1.21, 95% CI 1.05-1.39) and 2+ (HR = 1.80, 95% CI 1.56-2.08) comorbidities had inferior OS compared to those with no comorbidities after adjustment for age and sex (c-statistic = 0.654), and performance strengthened after adjustment for the International Prognostic Index (c-statistic = 0.672). LCI predicted OS most strongly in marginal zone (c-statistics = 0.748) and weakest in T-cell (c-statistic = 0.579) lymphoma. The cumulative incidence of death due to lymphoma, lymphoma treatment, and other causes all increased with increasing comorbidities, with the greatest increase observed for death due to other causes. The LCI performs comparable to other published comorbidity indices, supporting its use in the LEO cohort to better model real-world outcomes and more generally providing an approach to implementing comorbidity indices in cancer survivorship cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.